Search Results

You are looking at 1 - 10 of 491 items for :

  • Refine by Access: All x
Clear All
Full access

Unanswered Questions About Margin Recommendations for Primary Cutaneous Melanoma

Joyce Y. Wong and Vernon K. Sondak

excision of melanoma Evaluate different methods for the biopsy of melanoma and the role of expert pathologists Analyze surgical practices for melanoma Assess how to manage nevi among patients with melanoma Surgical removal remains the mainstay of

Full access

Controversies in the Management of Regional Nodes in Melanoma

George Plitas and Charlotte E. Ariyan

Lymph nodes are often the first site of melanoma metastases, and the presence of metastatic disease in the draining lymph node is the most powerful predictor of survival in patients with clinical stage I and II disease. 1 , 2 The field of

Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Overview In 2010, an estimated 68,130 new cases of melanoma were diagnosed and approximately 8700 patients died of the disease in the United States. 1 However, these figures for new cases may represent a substantial underestimation, because

Full access

Role of Dermatologists in Treating Melanoma

Allan C. Halpern and Sanjay K. Mandal

Cancer J Clin 2005 ; 55 : 10 – 30 . 2. de Vries E Coebergh JW . Melanoma incidence has risen in Europe . BMJ 2005 ; 331 : 698 . 3. Welch HG Woloshin S Schwartz LM . Skin biopsy rates and incidence of melanoma: population based

Full access

Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity

Richard D. Carvajal, Sharon A. Spencer, and William Lydiatt

Mucosal melanoma (MM) is an aggressive and clinically complex malignancy made more challenging by its relative rarity. Of the 68,130 cases of melanoma diagnosed in 2010 in the United States, only 0.8% to 1.8% of these arise from mucosal surfaces

Full access

Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity

Alice Zhou, Omar Butt, Michael Ansstas, Elizabeth Mauer, Karam Khaddour, and George Ansstas

Immune checkpoint inhibitors and BRAF-targeted therapies have redefined the management of malignant melanoma. Overall survival (OS) has increased significantly with immunotherapy, with >60 months reported. 1 Stabilization of the survival curve in

Full access

Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma

Robert H. I. Andtbacka and Jeffrey E. Gershenwald

Buzaid AC Soong SJ . Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma . J Clin Oncol 2001 ; 19 : 3635 – 3648 . 4 Balch CM Soong SJ Gershenwald JE . Prognostic factors analysis of 17,600 melanoma

Full access

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh

2016, an estimated 76,380 patients will be diagnosed with and approximately 10,130 patients will die of melanoma in the United States. 1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ

Full access

Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

Paul B. Chapman

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high

Full access

Review of Evidence-Based Support for Pretreatment Imaging in Melanoma

Michael S. Sabel and Sandra L. Wong

Edited by Kerrin G. Robinson

relevant financial relationships. References 1 Balch CM Soong SJ Gershenwald JE . Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001